Healthcare [ 13/13 ] | Drug Manufacturers - Specialty & Generic [ 100/164 ]
NASDAQ | Common Stock
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally.
It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, industrial, environmental, and agricultural customers.
In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers.
Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals.
Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.
It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors.
The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003.
Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | 0.31 Increased by +6.90% | 0.29 Increased by +6.90% |
| Mar 12, 24 | 0.33 Decreased by -2.94% | 0.28 Increased by +17.86% |
| Nov 8, 23 | 0.14 Decreased by -33.33% | 0.23 Decreased by -39.13% |
| Aug 30, 23 | 0.38 Increased by +46.15% | 0.38 |
| May 3, 23 | 0.29 Decreased by -12.12% | 0.34 Decreased by -14.71% |
| Feb 8, 23 | 0.34 Decreased by -8.11% | 0.30 Increased by +13.33% |
| Nov 9, 22 | 0.21 Decreased by -16.00% | 0.27 Decreased by -22.22% |
| Aug 24, 22 | 0.26 Decreased by -18.75% | 0.38 Decreased by -31.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 263.22 M Increased by +7.13% | 8.40 M Decreased by -16.30% | Increased by +3.19% Decreased by -21.87% |
| Dec 31, 23 | 249.94 M Increased by +2.17% | 1.27 M Decreased by -82.33% | Increased by +0.51% Decreased by -82.70% |
| Sep 30, 23 | 231.30 M Decreased by -0.53% | -8.00 M Decreased by -307.47% | Decreased by -3.46% Decreased by -308.56% |
| Jun 30, 23 | 255.05 M Decreased by -0.10% | 11.50 M Increased by +53.31% | Increased by +4.51% Increased by +53.46% |
| Mar 31, 23 | 245.70 M Increased by +2.54% | 10.04 M Decreased by -43.23% | Increased by +4.09% Decreased by -44.64% |
| Dec 31, 22 | 244.65 M Increased by +5.13% | 7.21 M Decreased by -58.72% | Increased by +2.95% Decreased by -60.73% |
| Sep 30, 22 | 232.52 M Increased by +8.32% | 3.86 M Decreased by -40.99% | Increased by +1.66% Decreased by -45.52% |
| Jun 30, 22 | 255.30 M Increased by +15.89% | 7.50 M Decreased by -56.14% | Increased by +2.94% Decreased by -62.15% |